Introduction
============

Periprocedural myocardial infarction (PMI) has had changing diagnostic criteria over the last decade. Elevation(s) in post--percutaneous coronary intervention (PCI) blood levels of markers of myocyte necrosis, preferably troponin T or I (TnT or TnI), were sufficient for the diagnosis of PMI using the 2000 and 2007 universal definitions of myocardial infarction (MI),^[@b1]--[@b3]^ but the 2012 universal MI definition requires features additional to biomarker elevations for the diagnosis. These include ischemic chest pain ≥20 minutes, ischemic ECG changes, and/or abnormal findings on either invasive or noninvasive imaging.^[@b4]^ Given that chest pain is very common post‐PCI in the absence of cardiac biomarker elevations, it has usually been assumed to be nonischaemic in origin. Conversely, some patients have cardiac biomarker elevations, but do not have either chest pain or observed changes in invasive or noninvasive imaging that would otherwise meet the criteria for the 2012 PMI definition.^[@b5]--[@b7]^

Recently, the Society for Cardiovascular Angiography and Interventions (SCAI) has developed PMI criteria similar to post--coronary artery bypass graft (CABG) MI criteria with biomarkers elevation ≥10× upper reference limit (URL) for creatine kinase MB (CKMB) and/or ≥70×URL for troponin.^[@b8]^ These PMI definition changes are likely to reduce the frequency of this event. The consequence of changing definitions may alter the prognostic significance of PMI.^[@b9]^ Also MI, including PMI, is often a component of the primary endpoint of clinical trials, so if PMI is a less‐frequent event, then trial costs may increase.

In order to evaluate the impact of using these different criteria to define PMI on event frequency, we examined post‐PCI levels of TnT and CKMB and other additional PMI criteria in the 2012 universal MI definition. The influence of PMI definition on late outcomes after PCI was also studied.

Methods
=======

Study Population
----------------

All patients undergoing PCI at the cardiac catheterization laboratories of Liverpool Hospital (Sydney, Australia) have clinical, angiographic, and procedural data recorded prospectively in cardiology and laboratory databases.^[@b10]^ These data include procedural indications, patient demographics, medications, angiographic and lesion characteristics, and stent types (drug‐eluting stent \[DES\] or bare‐metal stent). The current study includes patients undergoing PCI for stable coronary heart disease (CHD), unstable angina, and non‐ST‐segment elevation MI (NSTEMI) from October 1, 2003 to September 2010, who had qualifying cardiac biomarkers measurements before and after PCI. These included normal preprocedural TnT levels, or when pre‐PCI TnT levels were elevated, and 2 stable or falling levels 6 hours apart. Exclusion criteria included ST‐segment elevation myocardial infarction (STEMI), missing pre‐ and/or post‐PCI TnT results, post‐PCI TnT and/or CKMB measurements \>48 hours, or elevated pre‐PCI TnT levels within 72 hours that were not stabilized or falling ([Figure 1](#fig01){ref-type="fig"}). Post‐PCI outcomes are routinely assessed for quality assurance (project QA2008/034, approved by the Liverpool Hospital Ethics Committee).

![Study population. The diagram shows the patients from the total angioplasty cohort. Also, the reasons for exclusion from the current study for those who underwent PCI in the study period are shown. \*Fifty‐two patients had post‐PCI TnT \>5×URL. CHD indicates coronary heart disease; MI, myocardial infarction; NSTEACS, non‐ST‐segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PMI, periprocedural myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions; STEMI, ST‐segment elevation myocardial infarction; TnT, troponin T; URL, upper reference limit.](jah3-3-e001086-g1){#fig01}

PCI Procedures
--------------

Procedural details were as previously described.^[@b10]^ Stent deployment was performed according to our institutions\' DES selective use criteria,^[@b11]--[@b12]^ and angiographic successful procedures were defined as final post‐PCI minimum stenosis diameter reduction to \<20% in cases after stenting or to \<50% after balloon angioplasty in the presence of grade 3 Thrombolysis In Myocardial Infarction (TIMI) flow.^[@b13]^

Definition of PMI
-----------------

The 2007 universal MI definition of PMI merely required elevation of cardiac biomarkers, preferably TnT or TnI, post‐PCI (an ischemic setting),^[@b2]^ whereas the 2012 universal MI definition of PMI required ischemic chest pain ≥20 minutes, ischemic ECG change, and/or abnormal changes on either invasive or noninvasive imaging, in addition to elevations in cardiac biomarkers. The SCAI definition requires elevation of cardiac biomarkers, preferably CKMB ([Table 1](#tbl01){ref-type="table"}).^[@b4],[@b8]^ Among patients who met the TnT or CKMB criteria for diagnosis of PMI, as required for the 2012 universal MI definition and the SCAI definition, the data on ischemic chest pain and ischemic ECG changes were collected from the recorded cardiology databases. The angiographic and noninvasive imaging criteria for diagnosis of PMI, as required for the 2012 universal MI definition, included identifiable side‐branch occlusion (defined as ≤1 mm, \>1 to \<2 mm, and ≥2 mm), persistent or transient slow or no‐reflow, distal embolization, or dissection. These were reviewed by 5 experienced interventional cardiologists, and noninvasive imaging and disagreements were reviewed by a consensus panel of 3 (H.I., S.L., and J.F.), if necessary.

###### 

ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction and SCAI Definition With PCI

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    2007 Universal MI Definition      2012 Universal MI Definition                                                                SCAI Definition
  ------------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Biomarkers criteria                                                                                                                                                             

  Normal baseline values                            Elevation of TnT values \>3×URL   Elevation of TnT values \>5×URL                                                             Elevation of CKMB values ≥10×URL or TnT values ≥70×URL\
                                                                                                                                                                                  Elevation of CKMB values ≥5×URL or TnT values ≥35×URL[\*](#tf1-1){ref-type="table-fn"}

  Elevated baseline values, but stable or falling   Elevation of TnT values \>20%     Elevation of TnT values \>20%                                                               Increment rise of CKMB ≥10×URL or TnT values ≥70×URL

  Elevated baseline, but not stable or falling                                                                                                                                    Increment rise of CKMB≥10×URL or TnT values ≥70×URL[\*](#tf1-1){ref-type="table-fn"}

  Additional criteria                               Not required                      Ischemic chest pain ≥20 minutes or\                                                         New pathological Q‐waves in 2 contiguous leads or\
                                                                                      ischemic ECG changes or angiographic evidence:\                                             new persistent LBB in ECG
                                                                                      side‐branch occlusion\                                                                      
                                                                                      Slow flow or no‐reflow\                                                                     
                                                                                      embolization..... or\                                                                       
                                                                                      imaging evidence of new loss of viable myocardium or new regional wall motion abnormality   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; CKMB, creatine kinase MB; ESC, European Society of Cardiology; MI, myocardial infarction; PCI, percutaneous coronary intervention; SCAI, Society for Cardiovascular Angiography and Interventions; TnT, troponin T; URL, upper reference limit, WHF, World Heart Federation.

Additional criteria required.

Laboratory Assays
-----------------

Venous blood samples for TnT measurements were made using the third‐ and fourth‐generation TnT assay (Roche, Mannheim, Germany). Only patients with TnT and/or CKMB measured within 48 hours post‐PCI were included, and the highest value was included for the analysis. The URL for TnT using the third‐ and fourth‐generation assays (used before and after January 15, 2006, respectively) was 0.03 μg/L, defined as the level at \<10% coefficient of variation, complying with the European Society of Cardiology (ECS)/American College of Cardiology (ACC) consensus requirements.^[@b1]^

Clinical Follow‐up
------------------

Late clinical outcomes included death, MI, stent thrombosis (ST), and target vessels revascularization (TVR), defined as ischemia‐driven repeat revascularization of the culprit lesion, by PCI or CABG (as defined by the Academic Research Consortium).^[@b14]^ The composite of major adverse cardiac events (MACEs) include death/MI/TVR/ST, as previously reported.^[@b11]^ In brief, trained research staff (nurses or doctors) contacted patients, their relatives, or local physicians by phone and were asked about recurrent cardiac symptoms requiring hospitalization, particularly coronary revascularization, or MI. Data regarding death were obtained from family members, physicians, medical records, and death registry. Other clinical outcomes, such as repeated procedures for stent thrombosis and restenosis, were also evaluated and documented in our database.

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS (version 21; SPSS, Inc., Chicago, IL). Categorical variables were expressed as numbers and percentages per group, continuous variables as mean±SD for normally distributed variables, and medians and (25th and 75th percentiles) for skewed variables. For group comparisons, Pearson\'s chi‐square (χ²) test or Fisher\'s exact test were used, as appropriate, for unpaired categorical variables. McNemar\'s test was used for comparison of 2 related categorical variables and Cochran\'s Q test for comparisons of 3 related categorical variables. The Student *t* tests or the Mann‐Whitney\'s U tests (for skewed variables) were used for continuous variables.

Multivariable analysis was performed with the logistic regression analysis method to determine independent predictors of PMI. Variables with *P* values \<0.2 on univariable analysis were included in multivariable analysis models. These included age, sex, body mass index (BMI), hypertension (HTN), smoking, clinical indication for PCI, elevated pre‐PCI TnT level, an estimated pre‐PCI glomerular filtration rate (eGFR) \>30 to \<60 mL/min per 1.73 m^2^, using the MDRD formula (eGFR=186.3×SerumCr^−1.154^×age^−0.203^×0.742 \[if female\]),^[@b15]^ ACC/American Heart Association (AHA) class B2 and C lesions, calcified lesion, dissection, rotablation, pre‐PCI stenosis, culprit lesion length ≥20 mm, deployment of more than 1 stent, maximum deployment pressure duration, and TIMI 3 flow grade post‐PCI applied. Odds ratio (OR) and 95% confidence interval (CI) were reported.

Hazard ratios (HRs) with 95% CI were performed with Cox\'s regression analysis of the following events---death, MI, TVR, and ST---which represented MACEs and combined death or MI and at 30 days, 1 year, and 2 years in patients with, and without, PMI according to 2007 and 2012 universal MI definitions and the SCAI definition, respectively. Also, HRs for death and/or MI at 2 years were adjusted for age, pre‐PCI TnT level, and eGFR \>30 to \<60 mL/min per 1.73 m^2^. Five patients whose PCIs were unsuccessful as a result of failure to open chronic total occlusions, and 47 patients who were lost to follow‐up, were excluded from Cox\'s regression analysis of late clinical outcomes. Kaplan‐Meier\'s curves for late outcomes were compared using log‐rank testing. *P* values \<0.05 were considered statistically significant.

Results
=======

Patients Clinical and Procedural Characteristics
------------------------------------------------

This study included 742 patients who underwent PCI, 132 for stable CHD and 610 patients for acute coronary syndrome (315 NSTEMI and 295 unstable angina; [Table 2](#tbl02){ref-type="table"}). The mean age was 64±11 years, 74% were males, 28% had diabetes, and 60% had ACC/AHA class B2 and C lesions. Periprocedural GPIIb/IIIa inhibitors were used in 20% of PCIs, and in 97% of PCIs, at least 1 stent was deployed (32% had ≥1 DES); 4 patients had rotational atherectomy.

###### 

Baseline Demographic and Clinical Features of Patients With and Without PMI Using the 2007 and the 2012 Universal MI Definition and SCAI Definition

  Variable                                          All (n=742)       2007 Universal MI Definition   2012 Universal MI Definition   SCAI Definition                                                                                      
  ------------------------------------------------- ----------------- ------------------------------ ------------------------------ ----------------- ----------------- ----------------- ---------- ----------------- ----------------- -------
  Age, y[\*](#tf2-1){ref-type="table-fn"}           64±11             63±12                          68±11                          \<0.0001          64±12             68±10             0.001      64±11             69±8              0.087
  Male sex                                          552 (74)          431 (76)                       121 (70)                       0.166             484 (75)          68 (69)           0.162      539 (75)          13 (68)           0.595
  BMI, kg/m^2^[\*](#tf2-2){ref-type="table-fn"}     28 \[25 to 31\]   28 \[25 to 32\]                27 \[24 to 30\]                0.037             28 \[25 to 32\]   27 \[24 to 30\]   0.104      27 \[25 to 31\]   28 \[26 to 31\]   0.960
  Diabetes mellitus                                 209 (28)          160 (28)                       49 (28)                        0.915             176 (27)          33 (33)           0.220      202 (28)          7 (37)            0.394
  Cigarette smoker                                  166 (22)          134 (24)                       32 (19)                        0.176             147 (23)          19 (19)           0.415      164 (23)          2 (10)            0.273
  Hypertension                                      494 (67)          369 (65)                       126 (73)                       0.038             420 (65)          75 (76)           0.040      478 (66)          17 (89)           0.033
  Hyperlipidemia[\*](#tf2-3){ref-type="table-fn"}   533 (72)          410 (72)                       123 (71)                       0.915             463 (72)          70 (71)           0.789      517 (71)          16 (84)           0.224
  Family history of CHD                             136 (18)          109 (19)                       27 (16)                        0.309             121 (19)          15 (15)           0.380      130 (18)          6 (32)            0.136
  Previous PCI                                      98 (13)           75 (13)                        23 (13)                        0.942             82 (13)           16 (16)           0.351      95 (13)           3 (16)            0.729
  Previous CABG                                     75 (10)           55 (10)                        20 (12)                        0.450             64 (10)           11 (12)           0.722      72 (10)           3 (16)            0.428
  Clinical presentation                                                                                                                                                                                                                  
  Stable CHD                                        132 (18)          106 (19)                       26 (15)                        0.296             120 (19)          12 (12)           0.113      128 (18)          4 (21)            0.760
  Unstable angina                                   295 (40)          250 (44)                       45 (26)                        \<0.0001          274 (43)          21 (21)           \<0.0001   288 (40)          7 (37)            0.793
  NSTEMI                                            315 (42)          214 (37)                       101 (59)                       249 (39)          66 (67)           307 (42)          8 (42)     0.975                               
  Pre‐PCI TnT                                                                                                                                                                                                                            
  \<URL                                             492 (66)          405 (71)                       87 (51)                        \<0.0001          448 (70)          44 (44)           \<0.0001   481 (66)          11 (58)           0.432
  \>URL                                             250 (34)          165 (29)                       85 (49)                                          195 (30)          55 (56)                      242 (33)          8 (42)            
  eGFR                                                                                                                                                                                                                                   
  30 to \<60                                        196 (27)          141 (25)                       58 (35)                        0.010             160 (25)          36 (42)           0.001      186 (26)          10 (56)           0.012
  \<30                                              21 (3)            13 (2)                         8 (5)                          0.026             18 (3)            3 (3)             0.731      20 (3)            1 (6)             0.416

Values are expressed as n (%), unless otherwise indicated. Five patients with NSTEMI had shock, of whom 2 had PMI using either the 2007 or the 2012 universal definition and neither met the SCAI definition. BMI indicates body mass index; CABG, coronary artery bypass graft; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate (mL/min per 1.73 m^2^); MI, myocardial infarction; NSTEMI, non‐ST elevation myocardial infarction; PCI, percutaneous coronary intervention; PMI, periprocedural myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions; TnT, troponin T; URL, upper reference limit.

Mean±SD.

Median \[25th percentile to 75th percentile\].

Hyperlipidemia defined as previous diagnosis of hypercholesterolemia, including treatment with lipid‐lowering agents or fasting low‐density lipoprotein cholesterol of ≥130 mg/dL or total cholesterol of ≥200 mg/dL.

Patients with PMI, compared to those without, were more likely to have HTN, had more renal dysfunction (eGFR 30 to \<60 mL/min per 1.73 m^2^), had longer procedural time, and had ACC/AHA class B2 and C lesions. Demographic and angiographic characteristics of patients with, and without PMI, according to the 2007 and the 2012 universal definitions of MI and the SCAI definition, are shown in Tables [2](#tbl02){ref-type="table"} and [3](#tbl03){ref-type="table"}.

###### 

Angiographic and Procedural Characteristics of Patients With and Without PMI Using the 2007 and the 2012 Universal MI Definition and SCAI Definition

  Variable                                                                    All (n=742)       2007 Universal MI Definition   2012 Universal MI Definition   SCAI Definition                                                                                       
  --------------------------------------------------------------------------- ----------------- ------------------------------ ------------------------------ ----------------- ----------------- ----------------- ---------- ----------------- ------------------ ----------
  Culprit coronary artery                                                                                                                                                                                                                                           
  Left main                                                                   8 (1.1)           5 (0.9)                        3 (1.7)                        0.396             7 (1.1)           1 (1.0)           0.999      7 (1)             1 (5)              0.188
  LAD                                                                         293 (39)          222 (39)                       71 (41.3)                      0.583             257 (40.0)        36 (36.4)         0.495      287 (40)          6 (32)             0.475
  LCX[\*](#tf3-1){ref-type="table-fn"}                                        188 (2 5)         145 (25)                       43 (25)                        0.908             162 (25)          26 (26)           0.520      185 (26)          3 (16)             0.430
  RCA                                                                         219 (29)          173 (30)                       46 (27)                        0.363             190 (29)          29 (29)           0.959      213 (29)          6 (32)             0.842
  Bypass graft                                                                33 (4)            24 (4)                         9 (5)                          0.569             26 (4)            7 (7)             0.187      30 (4)            3 (16)             0.048
  B2/C Lesion (ACC/AHA)                                                       441 (60)          329 (58)                       112 (65)                       0.097             366 (57)          75 (78)           0.0001     425 (59)          16 (84)            0.027
  Proximal LAD lesion                                                         175 (24)          136 (24)                       39 (23)                        0.748             15 (24)           23 (23)           0.929      171 (24)          4 (21)             0.999
  Lesions at bifurcation                                                      153 (21)          113 (20)                       40 (23)                        0.330             134 (21)          19 (19)           0.706      148 (20)          5 (26)             0.565
  Lesions calcifications                                                      106 (14)          72 (13)                        34 (20)                        0.019             89 (14)           17 (17)           0.378      101 (14)          5 (26)             0.172
  Pre‐PCI coronary artery stenosis (%)[\*](#tf3-2){ref-type="table-fn"}       86±11             86±11                          88±10                          0.003             86±11             89±10             0.003      86±11             89±10              0.281
  Lesion length ≥20 mm                                                        311 (42)          226 (40)                       85 (50)                        0.025             254 (40)          57 (58)           0.001      303 (42)          8 (42)             0.985
  ≥1 drug‐eluting stent                                                       299 (32)          179 (32)                       50 (30)                        0.647             199 (32)          30 (32)           0.967      224 (32)          5 (29)             0.833
  \>1 stent                                                                   182 (24)          124 (22)                       58 (34)                        0.001             141 (22)          41 (41)           \<0.0001   175 (24)          7 (37)             0.276
  PCI duration (minutes)[\*](#tf3-3){ref-type="table-fn"}                     65 \[50 to 84\]   65 \[5 to 0\]                  70 \[55 to 95\]                0.0001            65 \[50 to 82\]   78 \[57 to 98\]   0.0001     64 \[50 to 82\]   90 \[77 to 100\]   0.0001
  Maximal deployment pressure (atm)[\*](#tf3-3){ref-type="table-fn"}          18 \[16 to 20\]   18 \[16 to 20\]                18 \[16 to 20\]                0.441             18 \[16 to 20\]   18 \[16 to 20\]   0.846      18 \[16 to 20\]   18 \[16 to 20\]    0.956
  Maximal deployment pressure duration (s)[\*](#tf3-3){ref-type="table-fn"}   25 \[20 to 30\]   25 \[20 to 30\]                26 \[20 to 30\]                0.070             25 \[20 to 30\]   25 \[20 to 30\]   0.403      25 \[20 to 30\]   30 \[20 to 30\]    0.191
  Glycoprotein IIb/IIIa inhibitor                                             149 (20)          105 (18)                       44 (26)                        0.040             122 (19)          27 (27)           0.055      142 (20)          7 (37)             0.080
  Rotablation                                                                 4 (0.5)           1 (0.2)                        3 (2)                          0.014             2 (0.3)           2 (2)             0.088      4 (0.6)           0 (0)              
  Dissection                                                                  28 (4)            6 (1)                          22 (12.8)                      \<0.0001          13 (2)            15 (15)           \<0.0001   23 (3)            5 (26)             \<0.0001
  TIMI 3 flow grade after PCI                                                 730 (99)          564 (99)                       166 (99)                       0.035             636 (96)          94 (94)           0.022      731 (99)          17 (94)            0.200
  Angiographic success                                                        723 (98)          556 (98)                       167 (98)                       0.746             627 (98)          96 (97)           0.439      705 (98)          18 (95)            0.326

Values are expressed as n (%), unless otherwise indicated. ACC/AHA indicates American College of Cardiology/American Heart Association; atm, atmospheres; LAD, left anterior descending coronary artery; LCX, left circumflex artery; MI, myocardial infarction; PCI, percutaneous coronary intervention; PMI, periprocedural myocardial infarction; RCA, right coronary artery; SCAI, Society for Cardiovascular Angiography and Interventions; TIMI, Thrombolysis in Myocardial Infarction.

Ten patients with ramus intermediate PCIs were included in the LCX group.

Mean±SD.

Median \[25th percentile to 75th percentile\].

Pre‐PCI TnT levels were \<URL in 492 (66%) and were elevated in 250 (34%) patients. PMI using the 2007 universal MI definition occurred in 172 (23%) patients (87 had post‐PCI TnT levels elevations \>3×URL, and 85 had \>20% elevation post‐PCI TnT levels), whereas PMI, based on the 2012 universal MI definition, occurred only in 99 (13%) patients (44 had post‐PCI TnT‐level elevations \>5×URL and 55 with elevated pre‐PCI TnT had \>20% increase post‐PCI levels). The most common additional criteria for the 2012 universal PMI definition was side‐branch occlusion in 53 patients (54%); side‐branch diameters were ≤1 mm in 48 patients, \>1 to \<2 mm in 3, and ≥2 mm in 2. Other reasons included persistent or transient slow or no‐reflow in 33% and 21% had distal embolization, whereas only 11% patients had ischemic chest pain and 12% had ischemic ECG changes; some had \>1 criteria ([Figure 2](#fig02){ref-type="fig"}). An additional 38 patients met the TnT elevation criteria for the 2012 universal MI definition of PMI without an additional feature (8 patients with normal pre‐PCI TnT levels and 30 with elevated pre‐PCI TnT levels). According to the SCAI definition, PMI occurred in 19 (2.6%) patients (11 with normal pre‐PCI TnT and 8 with elevated pre‐PCI TnT levels; 3‐way frequency comparison, *P*\<0.001). All 19 patients who fulfilled the SCAI definition of PMI fulfilled the 2007 universal definition of MI, but 2 of these did not fulfil the 2012 universal MI definition.

![Additional criteria for periprocedural myocardial infarction according to the 2012 universal MI definition. MI indicates myocardial infarction.](jah3-3-e001086-g2){#fig02}

Based on our previously reported correlation between CKMB and TnT using the equation: TnT (μg/L)=e^\[(1.202\[InCKMB\ μg/L\])−4.693+0.264(if\ eGFR\<30)\]^, when the pre‐PCI TnT level was \<URL, and the equation: additional TnT elevation (μg/L)=e^\[(1.103\[InCKMB\ μg/L\])−4.824+0.406(if\ eGFR\<30)\]^, when pre‐PCI TnT level \>URL,^[@b10]^ we found the PMI frequency based on biomarker levels of ≥10×URL for CKMB, which equates to TnT levels of ≥17×URL in females and ≥33×URL in males, occurred in 32 (4.3%) patients.

Independent predictors for PMI, based on the 2007 universal MI definition, on the multivariable logistic regression analysis model were coronary dissection, pre‐PCI (TnT) \>URL, age, and coronary artery stenosis (%) pre‐PCI. Applying the 2012 universal MI definition and using the same model identified ACC/AHA class B2 and C lesions and deployment of ≥1 stent as additional independent predictive factors. However, using the same model for the SCAI definition of PMI, the independent predictors were only coronary dissection and renal dysfunction (eGFR, \>30 to \<60 mL/min per 1.73 m^2^; [Table 4](#tbl04){ref-type="table"}).

###### 

Independent Predictors of Periprocedural Myocardial Infarction

  Variables                                OR (95% CI)             *P* Value
  ---------------------------------------- ----------------------- -----------
  2007 MI definition                                               
  Dissection                               10.72 (3.95 to 29.11)   \<0.0001
  Pre‐PCI troponin (TnT) \>URL             2.76 (1.81 to 4.19)     \<0.0001
  Age, y                                   1.03 (1.01 to 1.05))    0.001
  Coronary artery stenosis Pre‐PCI (%)     1.02 (1.00 to 1.04)     0.041
  2012 MI definition                                               
  Dissection                               5.04 (1.93 to 13.15)    0.001
  Pre‐PCI troponin (TnT) \>URL             3.24 (1.93 to 5.44)     \<0.0001
  Age, y                                   1.03 (1.01 to 1.05)     0.0
  Coronary artery stenosis Pre‐PCI, %      1.03 (1.01 to 1.06)     0.020
  Lesion B2/C type (ACC/AHA)               1.95 (1.07 to 3.57)     0.030
  \>1 stent                                1.84 (1.06 to 3.19)     0.031
  SCAI definition                                                  
  Dissection                               10.12 (2.88 to 35.55)   \<0.0001
  eGFR (mL/min per 1.73 m^2^) 30 to \<60   4.13 (1.51 to 11.25)    0.006

ACC/AHA indicates American College of Cardiology/American Heart Association; CI, confidence interval; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SCAI, Society for Cardiovascular Angiography and Interventions; TnT, troponin T; URL, upper reference limit.

Clinical Outcomes
-----------------

Late outcomes of death---recurrent MI, TVR, and MACE---were assessed at a median of 37 (interquartile range, 20 to 55) months post‐PCI and were not significantly different in patients with and without PMI, based on the 2007 universal MI definition ([Figure 3](#fig03){ref-type="fig"} and [Table 5](#tbl05){ref-type="table"}). Though according to the 2012 universal definition of MI, there was a trend toward worse outcomes in patients with PMI, compared to patients without PMI (death/MI at 2 years; *P*=0.059). However, the SCAI definition showed an increased frequency of death/MI at 2 years in patients with PMI, compared to those without (*P*=0.015; [Figure 3](#fig03){ref-type="fig"}). Kaplan‐Meier\'s analysis for death, MI, and the combination in patients with or without PMI, according to the 2007 and the 2012 universal MI definitions and the SCAI definition, are shown in [Figure 4](#fig04){ref-type="fig"}. The late events of death and/or nonfatal MI were more frequent in patients with normal pre‐PCI TnT, but not in patients with elevated pre‐PCI TnT levels, according to the 3 definitions of PMI ([Table 6](#tbl06){ref-type="table"}).

###### 

Different Definitions of PMI and Late Outcomes

  ----------------------------------------------------------------------------------------------------------------------------------
                                                     Patients Without PMI   Patients With PMI   HR and 95% CI            *P* Value
  --------------------------- ---------------------- ---------------------- ------------------- ------------------------ -----------
  2007 MI definition, n (%)   n=534 (77.4)           n=156 (22.6)                                                        

  30 days                     Death, n (%)\          3 (0.6)\               3 (1.9)\            3.43 (0.69 to 17.00)\    0.131\
                              MI, n (%)\             7 (1.3)\               3 (1.9)\            1.48 (0.38 to 5.70)\     0.573\
                              Death/MI, n (%)\       9 (1.7)\               5 (3.2)\            1.91 (0.64 to 5.71)\     0.245\
                              TVR, n (%)\            6 (1.1)\               2 (1.3)\            1.15 (0.23 to 5.96)\     0.865\
                              MACE, n (%)            11 (2.1)               6 (3.8)             1.88 (0.70 to 5.09)      0.213

  1 year                      Death, n (%)\          21 (3.9)\              6 (3.8)\            1.06 (0.43 to 2.64)\     0.903\
                              MI, n (%)\             26 (4.9)\              13 (8.3)\           1.77 (0.91 to 3.44)\     0.093\
                              Death/MI, n (%)\       45 (8.4)\              18 (11.5)\          1.422 (0.82 to 2.45)\    0.270\
                              TVR, n (%)\            32 (6.0)\              16 (10.3)\          1.80 (0.99 to 3.27)\     0.056\
                              MACE, n (%)            63 (11.8)              24 (15.4)           1.36 (0.85 to 2.18)      0.198

  2 years                     Death, n (%)\          25 (4.7)\              8 (5.1)\            1.14 (0.51 to 2.52)\     0.754\
                              MI, n (%)\             32 (6.0)\              17 (10.9)\          1.90 (1.05 to 3.42)\     0.033\
                              Death/MI, n (%)^\*^\   54 (10.1)\             23 (14.7)\          1.53 (0.93 to 2.49)\     0.090\
                              TVR, n (%)\            43 (8.1)\              18 (11.5)\          1.51 (0.87 to 2.62)\     0.142\
                              MACE, n (%)            79 (14.8)              29 (18.6)           1.32 (0.86 to 2.02)      0.202

  2012 MI definition, n (%)   n=601 (87.1)           n=89 (12.9)                                                         

  30 days                     Death, n (%)\          4 (0.7)\               2 (2.2)\            3.40 (0.62 to 18.56)\    0.158\
                              MI, n (%)\             7 (1.2)\               3 (3.4)\            2.94 (0.76 to 11.39)\    0.118\
                              Death/MI, n (%)\       10 (1.7)\              4 (4.5)\            2.75 (0.86 to 8.76)\     0.088\
                              TVR, n (%)\            7 (1.2)\               1 (1.1)\            0.98 (0.12 to 7.95)\     0.984\
                              MACE, n (%)            13 (2.2)               4 (4.5)             2.12 (0.69 to 6.49)      0.190

  1 year                      Death, n (%)\          24 (4.0)\              3 (3.4)\            0.90 (0.27 to 3.00)\     0.867\
                              MI, n (%)\             30 (5.0)\              9 (10.1)\           2.09 (0.99 to 4.40)\     0.052\
                              Death/MI, n (%)\       52 (8.7)\              11 (12.4)\          1.48 (0.77 to 2.84)\     0.236\
                              TVR, n (%)\            39 (6.5)\              9 (10.1)\           1.63 (0.79 to 3.36)\     0.187\
                              MACE, n (%)            74 (12.3)              13 (14.6)           1.24 (0.69 to 2.23)      0.480

  2 years                     Death, n (%)\          29 (4.8)\              4 (4.5)\            0.96 (0.34 to 2.72)\     0.933\
                              MI, n (%)\             37 (6.2)\              12 (13.5)\          2.28 (1.19 to 4.39)\     0.013\
                              Death/MI, n (%)^†^\    62 (10.3)\             15 (16.9)\          1.71 (0.97 to 3.01)\     0.062\
                              TVR, n (%)\            51 (8.5)\              10 (11.2)\          1.39 (0.71 to 2.75)\     0.337\
                              MACE, n (%)            91 (15.1)              17 (19.1)           1.33 (0.79 to 2.22)      0.287

  SCAI definition, n (%)      n=673 (97.5)           n=17 (2.5)                                                          

  30 days                     Death, n (%)\          6 (0.9)\               0 (0.0)\            0.05 (0.00 to 4583)\     0.796\
                              MI, n (%)\             8 (1.2)\               2 (11.8)\           10.24 (2.18 to 48.25)\   0.003\
                              Death/MI, n (%)\       12 (1.8)\              2 (11.8)\           6.84 (1.53 to 30.55)\    0.012\
                              TVR, n (%)\            7 (1.0)\               1 (5.9)\            5.82 (0.71 to 47.33)\    0.099\
                              MACE, n (%)            15 (2.2)               2 (11.8)            5.51 (1.26 to 24.12)     0.023

  1 year                      Death, n (%)\          26 (3.9)\              1 (5.9)\            1.52 (0.21 to 11.18)\    0.684\
                              MI, n (%)\             36 (5.3)\              3 (17.6)\           3.47 (1.07 to 11.26)\    0.039\
                              Death/MI, n (%)\       59 (8.8)\              4 (23.5)\           2.82 (1.03 to 7.77)\     0.045\
                              TVR, n (%)\            45 (6.7)\              3 (17.6)\           2.86 (0.89 to 9.19)\     0.078\
                              MACE, n (%)            82 (12.2)              5 (29.4)            2.72 (1.10 to 6.72)      0.030

  2 years                     Death, n (%)\          31 (4.6)\              2 (11.8)\           2.44 (0.58 to 10.19)\    0.222\
                              MI, n (%)\             46 (6.8)\              3 (17.6)\           2.75 (0.86 to 8.84)\     0.090\
                              Death/MI, n (%)^‡^\    72 (10.7)\             5 (29.4)\           2.92 (1.18 to 7.24)\     0.020\
                              TVR, n (%)\            58 (8.6)\              3 (17.6)\           2.23 (0.70 to 7.12)\     0.175\
                              MACE, n (%)            102 (15.2)             6 (35.3)            2.65 (1.63 to 6.04)      0.020
  ----------------------------------------------------------------------------------------------------------------------------------

CI indicates confidence interval; HR, hazard ratio; MACE, major adverse cardiac events; MI, myocardial infarction; PMI, periprocedural myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions; TVR, target vessel revascularization.

Adjusted HRs for death/MI at 2 years according to different PMI definitions were: \*2007 PMI definition, HR=1.3 (95% CI, 0.78 to 2.21; *P*=0.302); ^†^2012 PMI definition, HR=1.49 (95% CI, 0.80 to 2.76; *P*=0.208); ^‡^SCAI PMI definition, HR=2.70 (95% CI: 1.08 to 6.78, *P*=0.034).

###### 

PMI and Late Outcomes According to Pre‐PCI TnT Levels

                              Normal Pre‐PCI TnT   Elevated Pre‐PCI TnT                                        
  --------------------------- -------------------- ---------------------- ------- -------------- ------------- -------
  2007 MI definition, n (%)   n=382 (82.5)         n=81 (17.5)                    n=152 (67.0)   n=75 (33.0)   
  Death, n (%)                16 (4.2)             4 (4.9)                0.764   9 (5.9)        4 (5.3)       0.999
  MI, n (%)                   23 (6.0)             10 (12.3)              0.044   9 (5.9)        7 (9.3)       0.345
  Death/MI, n (%)             37 (9.7)             14 (17.3)              0.047   17 (11.2)      9 (12.0)      0.856
  TVR, n (%)                  37 (9.7)             10 (12.3)              0.472   6 (3.9)        8 (10.7)      0.075
  MACE, n (%)                 59 (15.4)            16 (19.8)              0.339   20 (13.2)      13 (17.3)     0.401
  2012 MI definition, n (%)   n=425 (91.8)         n=38 (8.2)                     n=176 (77.5)   n=51 (22.5)   
  Death, n (%)                18 (4.2)             2 (5.3)                0.675   11 (6.3)       2 (3.9)       0.738
  MI, n (%)                   26 (6.1)             7 (18.4)               0.012   11 (6.3)       5 (9.8)       0.364
  Death/MI, n (%)             42 (9.9)             9 (23.7)               0.025   20 (11.4)      6 (11.8)      0.937
  TVR, n (%)                  40 (9.4)             7 (18.4)               0.091   11 (6.3)       3 (5.9)       0.999
  MACE, n (%)                 65 (15.3)            10 (26.3)              0.077   26 (14.8)      7 (13.7)      0.852
  SCAI definition, n (%)      n=453 (97.8)         n=10 (2.2)                     n=220 (96.9)   n=7 (3.1)     
  Death, n (%)                18 (4.0)             2 (20.0)               0.065   13 (5.9)       0 (0)         0.999
  MI, n (%)                   31 (6.8)             2 (20.0)               0.155   15 (6.8)       1 (14.3)      0.405
  Death/MI, n (%)             47 (10.4)            4 (40.0)               0.017   25 (11.4)      1 (14.3)      0.578
  TVR, n (%)                  45 (9.9)             2 (20.0)               0.269   13 (5.9)       1 (14.3)      0.364
  MACE, n (%)                 71 (15.7)            4 (40.0)               0.062   31 (14.1)      2 (28.6)      0.270

MACE indicates major adverse cardiac events cardiovascular; MI, myocardial infarction; PCI, percutaneous coronary intervention; PMI, periprocedural myocardial infarction; TnT, troponin T; TVR, target vessel revascularization.

![Death/MI rate at 2 years based on the 2007 and 2012 universal MI definitions and SCAI definition. Kaplan‐Meier\'s analysis *P* values are reported for comparisons PMI versus no PMI. MI indicates myocardial infarction; PMI, periprocedural myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions.](jah3-3-e001086-g3){#fig03}

![Kaplan‐Meier\'s curve for death, MI, and combined death and MI. Actuarial outcomes for 690 patients are shown. Five patients who had unsuccessful PCI as a result of failure to recanalize chronic total occlusion and 47 (6.3%) had \<30 days follow‐up; those patients were not included in late Kaplan‐Meier\'s analysis. MI indicates myocardial infarction; PCI, percutaneous coronary intervention; PMI, periprocedural myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions.](jah3-3-e001086-g4){#fig04}

Discussion
==========

In this study, we report that the frequency of PMI was ≈60% lower using the 2012, compared to the 2007, universal MI definition and even lower using the SCAI definition. Based on the late outcome data, it appears that PMIs, which were identified using the 2007 universal definition of MI but did not qualify using the 2012 definition or SCAI definition, did not influence the rates of late death or MI. Whereas the universal definitions of PMI are not focused on prognosis, the SCAI definition has been based on post‐CABG prognosis.

The diagnosis of PMI using the 2012 universal MI definition requires post‐PCI TnT‐level elevation to \>5×URL, which corresponds to ≈3×URL for CKMB (mass). Using cardiac magnetic resonance (CMR) imaging, the threshold for detection is ≥3×URL for CKMB (mass), which has previously been reported to be prognostic.^[@b16]--[@b17]^ However, the SCAI definition requires post‐PCI TnT‐level elevation to ≥70×URL or CKMB ≥10×URL.^[@b8]^

Defining PMI, with respect of the amount of myonecrosis, has been traditionally based on CKMB (mass) levels. The equivalent extent of myonecrosis, in terms elevations in troponin levels, requires definition of which troponin assay T or I is used and, in particular, if a "conventional" or high sensitivity assay was performed. Additionally, in the case of TnI, detail of the assay manufacturer are also required. A recent study showed that post‐PCI troponin (various site assays) elevations to \>60×URL predicts similar risk of death to \>3×URL for CKMB,^[@b18]^ whereas we report here a less‐marked ratio between CKMB and TnT, perhaps reflecting use of the TnT assay. The relationship between TnT levels using the fourth‐generation Roche assay and the new "high‐sensitivity" TnT assay is not linear at levels \<5×URL, though these assays tend to correlate very highly at TnT levels \>10×URL, that is, ≈\>140 ng/mL (0.14 μg/L) using high‐sensitivity TnT. The SCAI definition sets similar biomarker criteria for PMI, whether post‐PCI or post‐CABG, whereas the mortality and the morbidity associated with these 2 procedures are different. Recently, the group from the Mayo Clinic have reported an adverse prognostic association with post‐PCI TnT elevations to \>0.25ng/L (25× URL), when the pre‐PCI TnT levels are normal.^[@b19]^ We have also shown that marked TnT elevations post‐PCI, when the baseline levels were normal, are associated with increased late death/MI occurrences, though number of events were small. Our findings are similar to those of others,^[@b18]^ in not finding such an association when pre‐PCI TnT levels were elevated. Further it seems plausible, though as yet unproven, that the prognostic importance of TnT elevations may vary with the degree of left ventricular dysfunction and/or haemodynamic instability. It is uncertain as to whether prognostic, rather than diagnostic, criteria for PMI will prevail.^[@b20]^

We found that the majority of the PMIs using the 2012 definition, which required imaging, were the result of small side‐branch occlusions, as previously reported.^[@b21]^ These were apparently unappreciated by the interventionalist performing the PCI. In routine clinical practice, these are not routinely reported given that the vessels were generally ≤1 mm in diameter and were only identified by careful review comparing the pre‐ and post‐PCI angiography. Nevertheless, the ensuing MIs are of a similar size in term of biomarker elevation to those previously reported on CMR and reported to be prognostic in an earlier era.^[@b22]--[@b23]^ Whereas PMI has an attributable risk for late mortality,^[@b9]--[@b10],[@b24]--[@b26]^ almost all the side‐branch occlusions identified were in vessels ≤1 mm, which were too small for side‐branch protection and/or intervention techniques. Further study is required to determine whether any strategies were feasible to reduce the frequency of these events, which has been previously reported to be an independent risk for late outcomes.^[@b27]^

Our study has some limitations. First, it is a single‐center study of PCI data collection, which limited study power, especially with respect to mortality. Second, these data were analyzed retrospectively and represent a subgroup of patients---those who had qualifying cardiac biomarkers measured. Operator‐requested biomarker assays may be more frequent in instances with clinical symptoms and complicated procedures that may have resulted in a degree of selection bias, leading to our relatively high reported incidence of PMI. Also, high‐sensitivity TnT assays only became available in June 2011. The duration of chest pain and slow flow/no‐reflow were not recorded, so we cannot specify how transient/persistent the reduced flow was. Pre‐PCI, in this CHD population, there was incomplete database recording of left ventricular (LV) function, and the failure to include an LV function parameter in multivariable analysis is a limitation---though, in this population, this factor is likely to be less important prognostically over 2‐year follow‐up than in a post‐STEMI cohort.

In conclusion, the 2012 universal definition of MI has reduced the frequency of PMI by ≈60%, compared with the 2007 universal MI definition. However, this reduction in PMI rate seems to be mainly the result of exclusions of events that were not prognostically significant. Furthermore, the main additional factor in the 2012 universal MI definition accounting for these PMI events was small side‐branch occlusion. The SCAI definition of PMI resulted in much fewer events, which were associated with a significantly increased rate of late adverse outcomes. Whether this PMI definition or the SCAI definition will achieve widespread acceptance awaits large, prospective studies.

None.
